Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2026 01:15 ET | Source: Basilea Pharmaceutica International Ltd, Allschwil

Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 05, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
August 05, 2026 01:15 ET | Source: Basilea Pharmaceutica International Ltd, Allschwil

Basilea erhält zusätzliche USD 5.4 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam

Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 05. August 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,...
July 29, 2026 01:15 ET | Source: Basilea Pharmaceutica International Ltd, Allschwil

Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 29, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
July 29, 2026 01:15 ET | Source: Basilea Pharmaceutica International Ltd, Allschwil

Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 30 Mio. für die Phase-3-Entwicklung des neuen Antipilzmittels Fosmanogepix

Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 29. Juli 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,...
July 28, 2026 08:30 ET | Source: Dyadic International, Inc.

Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
April 21, 2026 08:19 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease

NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering clinical-stage biotech company developing innovative therapies for inflammatory diseases, announces a...
December 11, 2025 08:46 ET | Source: ProteoNic Biosciences

ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

ProteoNic licenses its 2G UNic technology to Ginkgo Bioworks for a BARDA-backed consortium to boost fast, cost‑effective mAb production against filoviruses
December 11, 2025 05:00 ET | Source: Eukarys

Eukarÿs Wins 2025 BioTools Innovator Grand Prize and Joins BARDA’s Elite VANGUARD Program

Press Release Eukarÿs Wins 2025 BioTools Innovator Grand Prize and Joins BARDA’s Elite VANGUARD Program • Awarded the 2025 BioTools Innovator Grand Prize, receiving $250,000• Chosen by BARDA as a...
October 20, 2025 11:00 ET | Source: True Diagnostics, Inc.

True Diagnostics Awarded BARDA RRPV Project to Advance Rapid Biothreat Test

CARLSBAD, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- True Diagnostics, Inc. announced today that it has been awarded a Project Award through the Rapid Response Partnership Vehicle (RRPV) to advance...
August 26, 2025 05:00 ET | Source: Osivax

Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness

Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836 Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing...